LONDON – Building on FDA approval of its first human protein therapy, Pharming NV is expanding its pipeline with the €500,000 (US$666,300) cash acquisition of assets from a French company, Transgenic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results